Bro.... I've been here since 2008.
I'm just messing with ya. You are correct. My reading comprehension was deficient. Have a great weekend!
How old are you.... 15???
Your reading comprehension is terrible.
EXAS is NOT marketing Cologuard directly to patients and Wall Street.
You are a complete moron.
EXAS is targeting large healthcare delivery systems (HMO's) and the 2,000 physicians that write 60% of the current FIT/FOBT scripts.
You truly are an idiot.
I know high school kids with better knowledge bases than you.
Chuckie appears to be unaware of Columbia University sponsoring "Stool Testing for Pancreatic Cancer" with the Mayo Clinic.
Study Start Date: July 2009
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: December 2014
Principal Investigator: Wendy K. Chung, MD
Clinical Trials.Gov ID: NCT01104129
Your reading comprehension is poor.
The shorts are indeed potential "guaranteed" buyers.
That's why its NOT selling off on profit-taking heading into the close.
You guys are not alone.
I've spent hundreds of hours over the last 5 years telling people the EXAS story and how to "connect the dots". I've even told some very wealthy people too. I'd say that 95% of them have never bought a single share. It's a very strange socially-economic phenomena for sure. Makes you wonder if this is the same kind of mentality which goes into looking at their IRA's only once a year . . .
45% of the market for Cologuard comes from the Medicare population. Medicare has already announced a National Coverage Determination for Cologuard, earlier his month.
EXAS currently has a trial/study going on for IBD called "Oceana".
Chuckles... I'm shocked that you are totally unaware of this. KC has mentioned it on several calls earlier in the year. Congrats! You are now off to my IGNORE bin!
The stock traded up over $20 today and all of you beloved CEMI shareholders have missed the move while CEMI has gone nowhere. EXAS is +70% on the year.
Feel free to join the other 25 million shares of shorts who are getting squeezed into a monster "House of Pain"... many of whom have been short from $11, $12, $13, and $14.
Then be sure to understand that EXAS is developing a non-invasive cancer screening test for the entire GI tract, where these cancers claim 145,000 lives annually in the US alone. In fact, they already have "markers" that show 88% sensitivity for Pancreatic Cancer in PanC juice.
Remember, Cologuard will essentially replace the 10.5 million annual FIT tests performed... and the number is probably much higher given that so few comply and turn in their FIT tests EVERY YEAR.
Also don't forget, that 1 out of 1000 people who undergo colonoscopy DIE and 1 out of 100 return to the ER within 24 hours due to bleeding.
It is not a risk-free surgical procedure.
Yup, there is a pattern.
But I think that KC and Arora and Lidgard and Ahlquist know full well that they have a GRAND SLAM on their hands. The BoD won't be selling this company anytime soon!
Let's face it.... these clowns are incredibly stubborn.
I doubt that much more than 10-15% have covered since the FDA approval last Monday.
You are completely CLUELESS that over 10 Million FIT tests are performed ANNUALLY and that one needs to handle their own feces in order to swab the fecal material onto a cardboard test strip. Do your parents know that you play on the home computer while they are away at work?
Some don't think that USPSTF will be lowering the age to 40 anytime soon, but they haven't met since 2008 and won't meet again till next year. If they did mandate the screening age down to 40, Cologuard's addressable market would INCREASE by 50%!!!
I wonder if "Dave" is aware of the fact that the Cologuard assay does not include the usual $63 for bi-sulphate conversion of the DNA.... and the fact that both the BMP3 and NDRG4 markers are NOT being priced at $284 each, but $284 for BOTH.
Dylan Capel, a UW alum that was an assistant coach for the Badger's Varsity Crew passed away at age 23 in January of 2002 from colon cancer.